Repurposing of drugs can potentially bring medications with known safety profiles to new patient groups. What is the industry looking for when they consider to invest in a repurposing project? What is the regulatory framework in this area? How is IP handled?
Time and place: Oct. 9, 2019 5:00 PM–7:00 PM, Auditorium 2, Georg Sverdrups hus, Moltke Moes vei 39
The meeting is part of the SPARK Norway Educational Forum Series 3: Therapeutics and diagnostics – monthly open meetings organized by UiO:Life Science and SPARK Norway partners.
The questions above are among the questions that will be addressed in this seminar.
Olav Flaten, Hunemo/AURA Biopharm
Jan Petter Akselsen, The Norwegian Medicines Agency
Kirsten Stangebye and Eivind Roverud, Inven2